Figure 8.

Single-cell dissection of SCLC tumors with PCDHB4 expression

(A) UMAP plot of all SCLC tumor cells indicates the expression status of PCDHB4 in platinum-sensitive and platinum-resistant SCLC tumors.

(B) UMAP plot of all SCLC tumor cells indicates the expression status of PCDHB4 in SCLC tumors receiving vehicle and cisplatin treatment.

(C) Scoring of stemness and EMT gene signatures in platinum-sensitive and resistant SCLC tumors. The differences between groups were analyzed by Wilcoxon test and p < 0.05 was considered statistically significant.

(D) Scoring of stemness and EMT gene signatures in SCLC cells with or without PCDHB4 expression. The differences between groups were analyzed by Wilcoxon test and p < 0.05 was considered statistically significant.

(E) UMAP plots indicate the clustering of all cell types and the expression of PCDHB4 in all cell types. Bubble plot indicates that PCDHB4 is predominantly expressed in tumor cells.

(F) Scoring of stemness and EMT gene signatures in SCLC tumor cells with or without PCDHB4 expression. The differences between groups were analyzed by Wilcoxon test and p < 0.05 was considered statistically significant.

(G) Expression of PCDHB4 in tumor cells of each SCLC patient. The SCLC patients (P2, P4, P7 and P12) are divided into the group with high PCDHB4 expression. The SCLC patients (P1, P3, P5, P10, P11, P13, and P14) are divided into the group with low PCDHB4 expression.

(H) UMAP plot of all B cells, T/NK cells, and tumor cells indicates that the ratio of B cells or T/NK cells to tumor cells is higher in the group with low PCDHB4 expression.